Gilead Announces Dismissal of Securities Litigation

Gilead Sciences, Inc. (Nasdaq: GILD) today announced
that on May 12, 2006, Judge Martin J. Jenkins of the United States
District Court for the Northern District of California dismissed with
prejudice the securities class action complaint filed in 2003 against
Gilead and certain of its current and former officers, In re Gilead
Sciences Securities Litigation, Case No. C03-4999 MJJ. The complaint
had alleged that the defendants violated federal securities laws by
making allegedly false and misleading statements in 2003. The
plaintiffs have not indicated whether they will appeal the dismissal.

Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of unmet
medical need. The company's mission is to advance the care of patients
suffering from life-threatening diseases worldwide. Headquartered in
Foster City, California, Gilead has operations in North America,
Europe and Australia.

For more information on Gilead Sciences, please visit
www.gilead.com or call the Gilead Public Affairs Department at
1-800-GILEAD-5 (1-800-445-3235).